Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine if multiple doses of vancomycin over the course of 3 months will perturb the intestinal flora (microbiome) and result in reduced serum concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. The design of the study will permit investigators to assess the variability of serum uremic retention solute concentrations with and without antibiotic over a three-month period.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
New York University School of Medicine
New York, New York, United States
Start Date
November 27, 2017
Primary Completion Date
August 18, 2018
Completion Date
August 18, 2018
Last Updated
March 26, 2021
15
ACTUAL participants
Vancomycin
DRUG
Placebo
OTHER
Lead Sponsor
NYU Langone Health
NCT07146854
NCT04163614
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04580420